Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

Core Viewpoint - Appili Therapeutics Inc. announced the termination of the arrangement agreement with Aditxt, effective May 31, 2025, which may result in a termination fee of USD 1,250,000 payable by Aditxt [1][2]. Group 1: Termination of Arrangement Agreement - Aditxt delivered a notice to terminate the arrangement agreement dated April 1, 2024, with Appili and its subsidiary Adivir, with the termination effective as of May 31, 2025 [1]. - The termination fee due to Appili is USD 1,250,000, which will be reduced by amounts previously paid by Aditxt to extend the agreement's outside date, resulting in a net payable amount of USD 1,000,000 [2]. Group 2: Company Overview - Appili Therapeutics is a biopharmaceutical company focused on developing drugs for infectious diseases and medical countermeasures, aiming to address urgent infections with unmet needs [4]. - The company is advancing a diverse range of anti-infectives, including an FDA-approved metronidazole suspension, a vaccine candidate against biological threats, and a topical antiparasitic treatment [4].